{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T18:59:17Z","timestamp":1698433157685},"reference-count":75,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6672,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1994,12]]},"abstract":"<jats:p>In the treatment of hypertension in renally impaired patients, normalization of blood pressure alone may not be sufficient to prevent significant morbidity to the kidneys. Treatment must reduce pressure in the renal vasculature, otherwise glomerular filtration rate and renal plasma flow will continue to deteriorate. Isradipine, a dihydropyridine calcium\u2010channel blocker, has been investigated as a suitable treatment in this setting. Isradipine maintains glomerular filtration rate, preserves or enhances renal plasma flow, decreases renal vascular resistance, maintains or reduces filtration fraction, and exerts a sustained natriuretic effect, all of which may enable isradipine to slow the rate of progression of renal deterioration. In addition, isradipine may decrease proteinuria and may decrease glomerular capillary pressure by dilating both the efferent and afferent arterioles. Unlike older calcium\u2010channel blockers, isradipine exhibits minimal cardiodepressant activity and is not associated with any negative inotropic effects. It is metabolized in the liver and dosage adjustments may not be necessary when administered to patients with renal insufficiency. Isradipine has a favorable renal effect profile and also has several properties that meet the requirements of other patient populations where an extra measure of antihypertensive safety is required, such as diabetics, dialysis patients, and transplant recipients. Side effects with isradipine are usually mild and transient, occurring in a dose\u2010dependent manner.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1994.tb04727.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T19:58:03Z","timestamp":1362772683000},"page":"1164-1172","source":"Crossref","is-referenced-by-count":2,"title":["Calcium\u2010Channel Entry Blocker Therapy for Hypertensive Patients with Concomitant Renal Impairment: A Focus on Isradipine"],"prefix":"10.1002","volume":"34","author":[{"given":"William H.","family":"Frishman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"15","article-title":"Calcium channel blockers versus angiotensin\u2010converting enzyme inhibitors: Renal effects","volume":"16","author":"Linas S","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_1_3_2","first-page":"300","article-title":"Renal protection with calcium antagonism in essential hypertension","volume":"12","author":"Bauer JH","year":"1989","journal-title":"Clin Invest Med"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.19.5.403"},{"key":"e_1_2_1_5_2","first-page":"538","article-title":"Antihypertensive therapy and the progression of chronic renal disease: Are there renoprotective drugs","volume":"11","author":"Tolins JP","year":"1991","journal-title":"Semin Nephrol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(58)90306-1"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1970.03170330025003"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90944-Z"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.13.5_Suppl.I19"},{"key":"e_1_2_1_10_2","first-page":"569","article-title":"Hypertension with renal impairment: Influence of intensive therapy","volume":"63","author":"Pohl JEF","year":"1974","journal-title":"Q J Med"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1989.37"},{"issue":"27","key":"e_1_2_1_12_2","first-page":"S\u2010110","article-title":"Stockholm clinical study on progression of chronic renal failure: An interim report","volume":"36","author":"Bergstr\u00f6m J","year":"1989","journal-title":"Kidney Int"},{"key":"e_1_2_1_13_2","first-page":"45","article-title":"Hypertension and kidney disease: Effects of antihypertensive therapy","volume":"17","author":"Hall WD","year":"1991","journal-title":"Pract Cardiol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198223030-00002"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198937060-00005"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"96S","DOI":"10.1093\/ajh\/4.2.96S","article-title":"The place of isradipine in the treatment of hypertension","volume":"4","author":"Veld Man in't AJ","year":"1991","journal-title":"Am J Hypertens"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(88)90186-6"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199000402-00004"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)90080-4"},{"key":"e_1_2_1_20_2","first-page":"F619","article-title":"Effects of calcium antagonists on renal hemodynamics","volume":"249","author":"Loutzenhiser R","year":"1985","journal-title":"Am J Physiol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.8.3.238"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.11.6.639"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198803000-00008"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80250-2"},{"key":"e_1_2_1_25_2","first-page":"38S","article-title":"The effects of verapamil on renal blood flow, renal function, and neurohormonal profiles in patients with moderate to severe hypertension","volume":"3","author":"Kubo SH","year":"1986","journal-title":"J Clin Hypertens"},{"issue":"10","key":"e_1_2_1_26_2","first-page":"S154\u201061","article-title":"The natriuretic effect of the dihydropyridine calcium antagonist felodipine: A placebo\u2010controlled study involving intravenous angiotensin II in normotensive volunteers","volume":"10","author":"Sluiter HE","year":"1987","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.11.5.452"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(91)90712-T"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90193-9"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90192-7"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.10.6.577"},{"key":"e_1_2_1_32_2","first-page":"160","article-title":"Comparative effects of isradipine and enalapril on renal hemodynamics in essential hypertension [abstract]","volume":"45","author":"Ryan M","year":"1989","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"e_1_2_1_33_2","first-page":"S90\u20102","article-title":"Effects of long\u2010term administration of isradipine on renal hemodynamics and sodium metabolism","volume":"19","author":"Francischetti EA","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"e_1_2_1_34_2","first-page":"S93\u20105","article-title":"Long\u2010term antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function","volume":"19","author":"Wittenberg C","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"191S","DOI":"10.1093\/ajh\/4.2.191S","article-title":"Acute antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function","volume":"4","author":"Wittenberg C","year":"1991","journal-title":"Am J Hypertens"},{"issue":"3","key":"e_1_2_1_36_2","first-page":"S87\u20109","article-title":"Effects of isradipine on hypertension and renal hemodynamics","volume":"19","author":"Siamopoulos KC","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90184-8"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315405"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6545.471"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199000402-00006"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1159\/000167536"},{"key":"e_1_2_1_42_2","first-page":"F1157","article-title":"Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney","volume":"253","author":"Fleming JT","year":"1987","journal-title":"Am J Physiol"},{"key":"e_1_2_1_43_2","first-page":"F799","article-title":"Attenuation of endothelin effects by a chloride channel inhibitor, indanyloxyacetic acid","volume":"262","author":"Takenaka T","year":"1992","journal-title":"Am J Physiol"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199001183220315"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198910193211614"},{"key":"e_1_2_1_46_2","first-page":"495","article-title":"Endothelin\u20101 and the cardiovascular system: A mini\u2010review","volume":"4","author":"Nayler WG","year":"1989","journal-title":"J Appl Cardiol"},{"issue":"5","key":"e_1_2_1_47_2","first-page":"S205\u20106","article-title":"Effect of endothelin\u20101 on regional vascular resistances in the pig","volume":"13","author":"Pernow J","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_1_48_2","first-page":"F61","article-title":"Direct visualization of effects of endothelin on the renal microvasculature","volume":"258","author":"Loutzenhiser R","year":"1990","journal-title":"Am J Physiol"},{"key":"e_1_2_1_49_2","first-page":"F254","article-title":"Cardiovascular and renal actions of endothelin: Effects of calcium\u2010channel blockers","volume":"258","author":"Cao L","year":"1990","journal-title":"Am J Physiol"},{"key":"e_1_2_1_50_2","first-page":"129","article-title":"Renal consequences of antihypertensive therapy","volume":"11","author":"Eknoyan G","year":"1991","journal-title":"Semin Nephrol"},{"issue":"3","key":"e_1_2_1_51_2","first-page":"59","article-title":"Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy","volume":"64","author":"Insua A","year":"1988","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-9-707"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-12-987"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1159\/000168289"},{"key":"e_1_2_1_55_2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ajh\/5.5.318","article-title":"Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy","volume":"5","author":"Schmieder RE","year":"1992","journal-title":"Am J Hypertens"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.14.10.911"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.17.1.15"},{"key":"e_1_2_1_58_2","first-page":"481","article-title":"The effect of isradipine on glycemic control and blood lipids in black patients with type 1 diabetes","volume":"51","author":"Joubert PH","year":"1992","journal-title":"Curr Ther Res"},{"issue":"6","key":"e_1_2_1_59_2","first-page":"S213","article-title":"Isradipine\u2014a dihydropyridine calcium antagonist with a favorable metabolic profile in hypertensive type II diabetics compared to nifedipine [abstract]","volume":"12","author":"Janka H\u2010U","year":"1988","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370050063011"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198800356-00018"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00278492"},{"key":"e_1_2_1_63_2","first-page":"206a","article-title":"Verapamil increases cyclosporin\u2010A blood trough levels in cardiac transplant recipients [abstract]","volume":"11","author":"Angermann CE","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199019050-00004"},{"issue":"2","key":"e_1_2_1_65_2","first-page":"561","article-title":"Interaction of calcium blockers and cyclosporine","volume":"20","author":"Wagner K","year":"1988","journal-title":"Transplant Proc"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91594-1"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/6.10.725"},{"key":"e_1_2_1_68_2","first-page":"116","volume-title":"Book of Abstracts of the Fifth Congress of the European Society for Organ Transplantation.","author":"Vernillet L","year":"1991"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186662"},{"key":"e_1_2_1_70_2","first-page":"1453","article-title":"Interaction of cyclosporin and calcium antagonists","volume":"21","author":"Wagner K","year":"1989","journal-title":"Transplant Proc"},{"issue":"3","key":"e_1_2_1_71_2","first-page":"S38\u201045","article-title":"Tolerability of isradipine in the treatment of mild\u2010to\u2010moderate hypertension in general practice: A large\u2010scale surveillance study","volume":"19","author":"Hermans L","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_1_72_2","first-page":"2098","volume-title":"Physicians' Desk Reference.","year":"1993"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(88)90180-5"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.109"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(88)90193-3"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb05717.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1994.tb04727.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1994.tb04727.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T22:02:28Z","timestamp":1695852148000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1994.tb04727.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,12]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1994,12]]}},"alternative-id":["10.1002\/j.1552-4604.1994.tb04727.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1994.tb04727.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,12]]}}}